Thus, the regulation of RAS-RAF-ERK pathway by targeting the PHB-CRAF interaction introduces a novel potential therapeutic approach for ERK-driven pancreatic cancer. This evidence concerns the gene MAPK1 and familial pancreatic carcinoma.